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ABSTRACT
SYNTHESIS AND CHARACTERIZATION OF
CARBORANE-APPENDED BIOMOLECULES
Tirtha Raj Sibakoti, MS
Department of Chemistry and Biochemistry
Northern Illinois University, 2015
Dr. Narayan S. Hosmane, Director

A multi-step organic synthetic methodology to attach multiple boron-containing
carborane cages (boron source) to suitable biocompatible organic compounds (carriers) that can
be used for boron neutron capture therapy (BNCT) applications has been established. The
method involves alkylation of the selected organic compounds followed by conjugation with a
polyhedral carborane cage using a click reaction. To date, carborane derivatives of 4nitroimidazole, 2-nitroimidazole, phenothiazine, 1, 3, 4-thiadiazole-2, 5-dithiol, adenine, 6chloropurine and 3’, 5’-dihydroxyacetophenone have been successfully synthesized. In addition,
different coumarin derivatives were successfully synthesized using click chemistry. All products
were purified and isolated in good yields and characterized using Fourier-Transform Infrared
Spectroscopy (FTIR), Nuclear Magnetic Resonance (NMR), elemental analysis and Mass
Spectrometry (MS). These products could be made water soluble by decapitation of the
carborane cage in order for their biological evaluation.
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CHAPTER 1
BACKGROUND
The objective of this thesis was to develop a multi-step organic synthetic methodology to
synthesize carborane-appended biomolecules as drug delivery agents that would deliver a
sufficient amount of boron within tumor cells with least toxicity1. However, this work mostly
focused on the synthesis of novel carborane-appended biomolecules by applying click
chemistry2,3. Various organic compounds with different functional groups were selected as a
carrier because of their biocompatibility, lower toxicity and ease of functionalization. The
selected starting materials chosen as carrier compounds are 4-nitroimidazole, 2-nitroimidazole,
phenothiazine, 1,3,4-thiadiazole-2,5-dithiol, adenine, guanine, 6-chloropurine, 3’,5’dihydroxyacetophenone and coumarin derivatives. These compounds are of different nature, and
they would potentially target different receptors found on the surface of a tumor cell; however,
they all could increase the uptake of boron in some ways. They all also have a very good binding
affinity.
A synthetic methodology was developed to accomplish this goal. The initial step was to
perform the alkylation reaction of these selected compounds using propargyl bromide,
appropriate base and solvent, and then directly attach the decaborane on them. However, this
direct approach did not work as planned. Thus, determining different routes in order to attach
boron on the carrier compounds was important. Fortunately, click chemistry was taken as the
next approach and was successful. Click chemistry, previously known as Cu(I)I-catalyzed azide-
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alkyne cycloaddition reaction, is a simple reaction between terminal alkyne and azide functional
groups resulting in cyclic triazole ring with the use of a catalyst. In this case, 1-methyl-ocarborane was selected as a boron source, and following the literature, alkyl azide group was
incorporated into it. Carboranes are a class of heteroboranes that contains both boron (10 atoms)
and carbon atoms in clusters that can enhance the uptake of boron in a cell; they can easily be
functionalized and also they can be decapitated to make the carboranyl derivative water-soluble.
The combination of selected carrier compounds and carborane are complementary as the
hydrophilic selected carriers compensate for hydrophobicity of carboranes2. This newly
developed methodology has been successful in incorporating carborane into most of the carrier
agent. The compounds were purified and isolated in good yields and characterized using FourierTransform Infrared Spectroscopy (FTIR), Nuclear Magnetic Resonance (NMR), Mass
Spectrometry (MS) and elemental analysis.
In addition, all the compounds could be made water soluble by decapitating the carborane
cage in order for bio-distribution studies to investigate their applicationin medicinal chemistry,
particularly in boron neutron capture therapy (BNCT) for cancer treatment. Once the compounds
are water soluble, biological distribution studies will be performed in the near future in order to
calculate the boron uptake and determine if they are potential cancer therapeutics. Cytotoxicity
of few compounds has been tested and found to be non-toxic in the various cancer cell lines.
Furthermore, suitable compounds could be encapsulated with the liposomes to make the drug
delivery feasible and effective. Various other organic compounds could also be selected as a
starting material in order to synthesize more carborane-appended biomolecules with the
established methodology.
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CHAPTER 2
CARBORANES
2.1 Introduction
Carboranes (C2B10H12) belong to the heteroboranes family, which consists of two carbon
atoms, ten boron atoms and twelve hydrogen atoms1. The carboranes are polyhedral clusters
which exhibit icosahedral structure (20 faces, 30 edges and 12 vertices) 4. The presence of two
carbon atom in carboranes allows various organic modifications. The hydrogens bonded to the
carbons in the carborane cage are acidic, allowing their easy removal using strong bases, thus
yielding several derivatives of clusters. These icosahedral dicarbaboranes can be easily
functionalized and have been frequently applicable in medicinal chemistry5. Therefore,
carboranes are of great interest for boron chemists to look into for their research. The most
common applications can be observed in materials science, novel drug discovery, catalysis and
polymers.
2.2 Nomenclature and Different Forms
In general, nomenclature of carboranes is represented by C2BnHn+2, where n is an
integer4. Carboranes with n ranging from 3 to 12 have been synthesized and characterized. The
numbering of the atoms in carboranes starts with the atom of lowest coordination with fewest
bonds, and numbering polyhedral vertex atoms in a clockwise direction (carbon atoms being
given the lowest possible numbers). The systematic (IUPAC) name of carboranes is given as
closo-dicarbadodecaborane.
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Carboranes exist in three different isomeric forms as ortho-, meta-, and para- isomers,
which only differ in the relative position of carbon atoms in the cluster as shown in Figure 1.
Most commonly, ortho- and meta- forms of these clusters are used to obtain their derivatives.
Ortho-carboranes are the most extensively studied of all forms of carboranes.

Figure 1: Structure of ortho-, meta-, and para- carborane isomers

Generally, structures of carboranes can be predicted based on electron counting rules known
as “Wade’s rules”5. Application of Wade’s rules will provide a relatively simple relationship
between the number of skeletal bonding electron pairs and the geometry of a carborane
molecule, which is shown in Table 1 below, where x is occupied vertices.
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Table 1
Summary of Electron-counting Rules
Structure types

Skeletal electron pairs

closo

x+1

Nido

x+2

Arachno

x+3

Carboranes are classified into three geometric categories; closo, nido and arachno. The closo
(closed) carboranes are more thermally stable and less air sensitive compared to nido (open) and
arachno forms as they lack closed polyhedral structures6, 7, 8. The skeletal atoms occupy all
corners of a polyhedron in closo structures, while in nido, one corner of the polyhedron is vacant
as shown in Figure 2 below (n=12). Additionally, if two vertices are removed from the closo
structure, it will result in the arachno form of carborane9.

6

Closo

Figure 2:

Nido

Arachno

Schematic polyhedral atomic structures of closo, nido, and arachno carboranes
showing conventional numbering schemes
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2.3 Synthesis of Carboranes
The first carboranes were synthesized by the reaction between pentaborane (B5H9) and
acetylene (C2H2) in an electric glow discharge10, 11. This reaction is shown in equation 1.
B5H9 + C2H2 → 1,5-C2B3H5 + 1,6-C2B4H6 + 2,4-C2B5H7 …….(1)
According to the literature published,carboranes can be synthesized by reacting
decaborane (B10H14) with acetylene in presence of Lewis base and appropriate solvent to yield
ortho-carborane along with a release of hydrogen gas12. Thermal isomerization of the ortho
isomer in an autoclave under inert conditions can yield meta isomer around 500°C and para
isomer around 700°C as shown in Scheme 1.

Scheme 1:

Synthesis of the carborane isomers [12]
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Carborane is a source of boron in this work. Commercially available 1-methyl-ocarborane was used for the purpose of synthesis of carboranylazide that will be incorporated into
various organic compounds in order to obtain their carborane-appended derivatives. These
carborane-appended biomolecules could be applicable in cancer treatment by using a popular
technique called BNCT that utilizes boron drugs and a neutron source for selectively killing
cancer cells via production of highly energetic alpha particles and gamma rays through nuclear
fission reaction. Various carborane-appended biomolecules have been synthesized as of today;
however,this has not been successfully applicable in BNCT cancer treatment. Sodium
borocaptate (Na2B12H11SH), most popularly known as BSH, is one of the FDA approved boron
drugs available in the market; however, BSH has toxicity issues. Therefore, in order to design a
new boron drug for effective BNCT, more emphasis should be given to the boron content, carrier
biocompatibility, water solubility and biological activities before getting in to clinical trials.
Carboranes are a very important source of boron in BNCT because of their high boron content
(10 boron atoms) and their ease of functionalization.

2.4 Decapitation and Bio-distribution
Commercially available ortho-carborane clusters can be decapitated in the presence of an
appropriate base to the monoanionic [nido- 7, 8-C2B9H12] - by the removal of one boron atom as
illustrated in scheme 3. In order to produce dianionic species [nido- 7, 8-C2B9H12]2-, a somewhat
acidic hydrogen bridge in [nido- 7, 8-C2B9H12]– can be removed by treating with a strong base
such as butyllithium, sodium hydroxide or potassium hydroxide as shown in Scheme 2 below13.
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Scheme 2:

Conversion of closo-carborane to nido- form

After the synthesis of carborane-appended biomolecules and their cage opening, a
biological distribution study needs to be performed in order to check their cytotoxicity and other
biological activities in cell lines and for further animal studies14. Bio-distribution studies
provides information about the uptake of boron by cell which is an important parameter to be
determined before BNCT applications.
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CHAPTER 3
BORON NEUTRON CAPTURE THERAPY (BNCT)
3.1 Introduction
Neutron capture therapy (NCT) was introduced in 1936, four years after Sir James
Chadwick discovered the neutron. Boron (B) and Gadolinium (Gd) are two ideal candidates that
can be used as a capture agent for NCT because of their high neutron capture cross section.
Neutron capture therapy had been utilized in the treatment of various types of cancers.
Chemotherapy, radiation therapy, and surgery have had some success in treating cancer;
however, these treatments do not selectively kill the cancer cells. Therefore, a technique that can
selectively destroy the cancer cell is required. Thus, doing more research in other potential
cancer therapies is important, one of which is BNCT that utilizes boron-10 nuclei. A few years
after Sir James Chadwick discovered neutrons, H.J. Taylor (in 1935) discovered that boron-10
could capture the thermal neutrons. Additionally, one year later, G.L. Locher understood the
therapeutic potential of this finding and proposed that neutron capture could be used to treat
tumors, which led to BNCT. This technique is binary radiation therapy, because it utilizes 10B
enriched drug and thermal neutrons at the same time15. Boron has two isotopes in nature, 10B
(20% abundance) and 11B (80% abundance), so its ready availability makes it an ideal candidate
for BNCT. In BNCT, a 10B enriched compound is transported into cancer cells where it absorbs
low energy thermal neutrons upon irradiation to form an excited but less stable (10-12 sec) 11B
nucleus. This 11B nucleus will quickly undergo nuclear fission reaction and disintegrate into
highly energetic alpha particles and recoiled lithium ions along with low energy of gamma ray as
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shown in Figure 3. The unique properties of this technique is that path length of the radiation (~
9 µm) corresponds to the dimensions of a single cell, hence selectively killing targeted tumor
tissues while sparing neighboring healthy ones. In order for BNCT to work effectively, it has to
meet several requirements such as concentration of boron within tumor cells, minimal toxicity
and water solubility. There are only limited boron drug delivery agents available in the market
today, and they are not very effective, so it should be a priority to overcome such drawbacks and
find alternatives.

Figure 3:

Boron Neutron Capture reaction: Emission of 1.47MeV α-particle, 0.84MeV Liparticle, and 0.48 MeV γ-rays

3.2 Why Boron?
In 1808, Gay-Lussac and Thenard first isolated boron, and Sir Humphry Davy discovered
this element independently when he reacted boric acid with potassium1.Boron is classified as
metalloid because of its resemblance as both metal and non-metal. It is an only non-metal
element located in the group 13 and is the fifth element of the periodic table. Boron has two
isotopes, 10B and 11B, which differ from each other by 1 neutron. 10B is 20% abundant in nature
while 11B is 80% abundant2. 10B has five neutrons, whereas 11B has 6 neutrons as shown in
Figure 4 below.
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Why is boron an ideal candidate for neutron capture reaction? In neutron capture
reaction, neutrons gets absorbed initially, which forms a heavier nucleus and the neutron capture
cross-section is the parameter used to measure the probability of neutrons absorption.

Figure 4:

Isotopes of Boron [18]

The higher the neutron’s capture cross-section, probability that the nuclide will absorb
the neutron is also higher. Boron has a neutron capture cross section of approximately 4000
barns1. As shown in Table 2 below, 10B is the most suitable nuclide for neutron capture therapy
because of its higher neutron capture cross-section. 10B is non-radioactive and is 20% naturally
abundant which makes it readily available. Alpha particles and lithium produced after neutron
capture reaction have high linear energy transfer (LET) 2. Moreover, the path length of the
radiation corresponds to the diameter of a cell size, thus radiation effect can be localized to the
targeted tumor cell while sparing healthy ones. Additionally, boron chemistry also allows
incorporation of different chemical structures into it far more easily.
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Table 2
Thermal Neutron Capture Cross-section Values of
Potential Nuclides for Neutron Capture Therapy
Nuclide
10
B
11
B
12
C
1
H
14
N
35
Cl
23
Na
157
Gd
153
Gd

Cross section (barns)
3837.00
0.01
0.00
0.33
1.70
43.60
0.53
254000.00
0.02

3.3 Neutron Source
In the early days, low energy thermal neutron was used for the irradiation. Later in Japan,
an epithermal neutron beam was used as it had better tissue penetrating properties1.Therefore,
epithermal neutrons have been preferred in BNCT clinical trials. An epithermal neutron beam
has a kinetic energy slightly less than one kilo-electron volt. Schematic of epithermal neutron
beam is shown below in Figure 5.

Figure 5:

Pathway of neutrons [18]

As observed in the diagram above, fast neutrons are in the nuclear reactor which then
passed through a moderator material, rich in hydrogen. This moderator helps to slow down the
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fast neutrons into the epithermal neutron. Finally, the neutron is absorbed by a10B compound
placed in the tumor, thus killing the cells.
3.4 How BNCT Works
The schematic diagram of how BNCT works is illustrated in the Figures 6 and 7 shown
below. Initially compound containing Boron-10, is transported into the tumor cells using a
suitable delivery agent, which is then followed by irradiation of neutrons17. Therefore, this
technique is referred to as a binary radiation therapy. Upon irradiation, neutrons are absorbed by
10

B which becomes excited to 11B. These 11B isotopes of boron areless stable and only remain

for 10-12 s. 11B undergoes fission reaction and rapidly disintegrates into highly energetic helium
ions (alpha particles) and highly recoiled lithium-7, along with gamma rays18. The radiation
path-length (~9 μm) of these particles corresponds to the diameter of cell size, meaning it is
compatible within a cell and could destroy targeted cells only. Only the cell concentrated with
10

B is destroyed as shown in Figure 6. In order for BNCT to work effectively, 109 10B atoms

(~30µg/g tumor tissue) must be delivered to tumor cells17. On the other hand, 1012 neutrons per
square centimeter are needed. This is why this technique is unique and could be effective if
requirements are met.

15
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Figure 6:

Schematic diagram of BNCT reaction in a cell.
produces Li particles and alpha particle [18]

B absorbs thermal neutrons and

Figure 7:

Schematic diagram of localized effect in a tumor cell. A tumor is selectively
killed sparing healthy cells [18]

16
3.5 BNCT Procedure
The invasive nature of the cancer makes the treatment difficult. BNCT is one of the
unique and promising methods of cancer treatment, as it could selectively destroy the tumors.
Before BNCT, surgery and chemotherapy should be performed in either order as illustrated in
Figure 8. Generally, surgery is recommended to be performed 3-4 weeks prior to doing BNCT.
Initially, the drug will be infused in to the patient’s body through an effective means and it will
take two hours for the completion of drug infusion, and then BNCT can start after approximately
45 minutes after the end of infusion. Usually, one session of BNCT takes approximately one
hour19. There are various challenges that lie in doing BNCT, especially in regards to targeting the
tumor cell, matching the boron concentration requirement, and irradiating with a sufficient
amount of neutrons required for a nuclear fission reaction.

Figure 8:

Treatment strategies for malignancies [18]
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3.6 Boron Delivery Agents
Various challenges lie in fulfilling the requirement for BNCT to work effectively. Firstly
and most significantly, boron concentration of 30-35µg 10B/g tumor tissue is required20. Low
systemic toxicity, high tumor uptake, rapid clearance from blood and normal tissue and retention
during irradiation are among others. Unfortunately, there are no drug delivery agents which meet
all these criteria. Boric acid and its derivative were initially used in clinical trials of the 1950s
and early 1960s; however, these molecules were not selective, had poor tumor retention, and low
tumor/brain ratios21. Boronophenylalanine (BPA) and sodiumborocaptate (BSH)are the only
FDA approved boron drug in the market as of now.BPA has low boron content, while BSH has
thiol group which couldbe linked with another thiol group and form disulfide linkage and can
damage DNA. The structures of BPA and BSH are shown in Scheme 3 below.

Scheme 3:

Structure of BPA (boronphenylalanine) and BSH (Sodium borocaptate)
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Therefore, boron enriched compound is required for the effective treatment of cancer. It
is our primary goal to design a new drug by considering the requirements of an effective
borondelivery agent for BNCT. There are two different and important category in this aspects,
one being boron delivery agent and another boron source which is carborane in our work.
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CHAPTER 4
SYNTHESIS OF CARBORANYL AZIDE
The boron source used in our work is commercially available 1-methyl-o-carborane.
Multi-step synthesis was performed with this compound to obtain carboranyl azide (compound
2) required for click reaction. Initially, our starting material was treated with 1,4-diiodobutane in
presence of base, butyl-lithium to produce an intermediate 1, which was then reacted with
anhydrous sodium azide in presence of acetone to give compound 2 as shown in Scheme 4
below2. Compound 2 is our boron source used for the synthesis of carborane-appended
biomolecules in this work.

Scheme 4:

A reaction scheme showing synthesis of carborane-appended azide compounds
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CHAPTER 5
SYNTHESIS OF ALKYNYL COMPOUNDS
Alkylation reaction was performed with all of our selected organic compounds in order to
synthesize their alkynyl derivatives required for click reaction. Various organic compounds with
different organic moieties are selected as a starting material. Organic compounds containing
imidazole, secondary amine, thiols, nucleobases and dihydroxy group are selected because of
their biocompatibility, less toxicity and ease of functionalization. Structures and names of the
selected starting organic compounds are shown in Scheme 5 below. The properties of these
selected compounds are discussed below.

Scheme 5:

Structures and names of selected organic compounds
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Imidazole is a heterocyclic compound that resembles a five-membered ring structure
composed of three carbon atoms and two nitrogen atoms at non-adjacent positions and has a
colorless to pale yellow appearance22. Out of two nitrogen atoms in imidazole, one is slightly
acidic and another is basic. They are usually soluble in organic compounds such as chloroform.
The derivatives of imidazole are widely applicable in the synthesis of organic compounds
especially in pharmaceuticals. Therefore, nitro derivatives of imidazole have been selected in
order to incorporate them with carborane in order to investigate their potential use as boron
delivery agents in BNCT.
Nitroimidazoles, generally known as azomycins possess significant medicinal
applications as they could be attached with different functional groups and their derivatives
could be synthesized to evaluate their tumor imaging properties23. 4-nitroimidazole is an organic
compound with the formula C3H3N3O2 and is one of the most common isomers of imidazole
containing one nitro group. 4-nitroimidazole was treated with propargyl bromide and anhydrous
potassium carbonate in acetone in order to synthesize a terminal alkyne derivative (compound 3)
required for its click reaction with carboranyl azide. The reaction scheme is shown in Scheme 6
below.

Scheme 6:

Alkylation reaction of 4-nitroimidazole using propargyl bromide
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Similarly, 2-nitroimidazole is an organic compound with the formula C3H3N3O2 and is
another common isomer of imidazole containing one nitro group. Generally, 2-nitroimidazole is
soluble in organic solvents such as DMSO or ethanol or chloroform. 2-nitroimidazole was
treated with propargyl bromide and anhydrous potassium carbonate in acetone in order to
synthesize terminal alkyne derivative required for its click reaction with carboranyl azide. The
reaction scheme is shown in Scheme 7 below.

Scheme 7:

Alkylation reaction of 2-nitroimidazole using propargyl bromide

Phenothiazine is a tricyclic organic compound with the formula S(C6H4)2NH which
belongs to thiazine-class of heterocyclic compounds. This compound was first prepared in 1883
by Bernthsen via the reaction between diphenylamine and sulfur; however, cyclization of 2substituted diphenyl sulfides is more popular recently24. It is yellow in appearance and mostly
soluble in benzene, ether and acetic acid. Phenothiazine derivatives have been found to have
significant uses as drugs. Thus, phenothiazine was selected as a starting material in our research
to attach carborane in to it for evaluating their use as a boron drug.
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Phenothiazine was treated with propargyl bromide and anhydrous potassium carbonate in
acetone in order to synthesize terminal alkyne derivative required for its click reaction with
carboranyl azide. The reaction scheme is shown in Scheme 8 below.

Scheme 8:

Alkylation reaction of Phenothiazine using propargyl bromide

1, 3, 4-thiadiazole-2, 5-dithiol is another organic compound with the chemical formula of
C2H2N2S3 and selected in this work because this moiety exhibits various physiological activities.
This compound contains thiadiazole rings, which has three donor centers for the two N atoms
and the heterocyclic S atoms, and two thiols which are equivalent sterically25. Thus, it makes this
compound highly nucleophilic, and it is interesting to introduce other functional groups in order
to synthesize their derivatives. Synthesis of carborane-appended derivative of this compound is
promising and could produce a new compound with broad spectrum of biological activity
according to our hypothesis. Our hypothesis is to introduce terminal alkyne group in to each thiol
end of this compound and incorporate carboranylazide (Compound 2) via a click reaction in
order to derive a boronated biomolecule.
1, 3, 4-thiadiazole-2, 5-dithiol was treated with propargyl bromide and anhydrous
potassium tert-butoxide (2 equivalent) in acetonitrile in order to synthesize the terminal alkyne
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derivative required for its click reaction with carboranyl azide. The reaction scheme is shown in
Scheme 9 below.

Scheme 9:

Alkylation reaction of 1, 3, 4-thiadiazole-2, 5-dithiol using propargyl bromide

Adenine, one of the most important organic molecules for life, is one of the purine
nucleobase with chemical formula C5H5N5 which is significantly important in a variety of roles
in biochemistry. Adenine is used in forming nucleotides of the nucleic acids, binds to thymine
and uracil in DNA and RNA respectively. Adenine can also be attached with ribose and
deoxyribose to form adenosine and deoxyadenosine (nucleosides) respectively. In addition,
adenosine triphosphate (ATP), a nucleotide, can be formed when adenosine is attached with
three phosphate groups which is useful in cellular metabolism.Adenine was first named by
Albrecht Kossel in 1885 and in 1961 by Joan Oro when he synthesized adenine from the
polymerization of ammonia with five hydrogen cyanide (HCN) molecules in aqueous solution.
Derivatives of adenine containing compound are found to be applicable in medicinal
chemistry because of their reaction with receptors26. Therefore, we have selected adenine as one
of our strating organic compounds to attach carborane. Adenine was treated with propargyl
bromide and anhydrous potassium carbonate in dimethylformamide (DMF) in order to
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synthesize terminal alkyne derivative required for its click reaction with carboranyl azide. The
reaction scheme is shown in Scheme 10 below.

Scheme 10:

Alkylation reaction of adenine using propargyl bromide

Similarly, guanine another purine nucleobase with the chemical formula C5H5N5O
consists of a fused pyrimidine-imidazole ring system with conjugated double bonds. Guanine
along with adenine is also present in both DNA and RNA, where it binds to cytosine through
three hydrogen bonds. It was named in 1846, two years after its reported isolation from the
excreta of sea birds. Guanine can be synthesized in trace amounts by the polymerization of
ammonium cyanide (NH4CN)27.
Guanine derivatives are also significantly important in novel drug discoveries. Thus,
guanine is also our selected compound to test proposed hypothesis in order to synthesize its
carborane-appended derivatives. Guanine was treated with propargyl bromide and anhydrous
potassium carbonate in dimethylformamide (DMF) in order to synthesize terminal alkyne
derivative required for its click reaction with carboranyl azide. The reaction scheme is shown in
Scheme 11 below.
6-chloropurine is a purine derivative with a formula C5H3ClN4 and soluble in
dimethylformamide (DMF) and ether. The derivative of this compound has also been found
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Scheme 11:

Alkylation reaction of guanine using propargyl bromide

applicable in medical science. The alkylation reaction of this compound is a feasible way to
obtain one of its derivatives among others. 6-chloropurine was treated with propargyl bromide
and anhydrous potassium carbonate in dimethylformamide (DMF) in order to synthesize
terminal alkyne derivative required for its click reaction with carboranyl azide. The reaction
scheme is shown in Scheme 12 below.

Scheme 12:

Alkylation reaction of 6-chloropurine using propargyl bromide

3’, 5’-dihydroxyacetophenone, white to light yellow crystal powder in appearance, is a
dihydroxy derivative of acetophenone. This compound has also been applicable in medicinal
chemistry as it shows some antitumor activity. Thus, we have used this compound in order to
derive its derivatives that could be useful in cancer treatment. 3’, 5’-dihydroxyacetophenone was
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treated with propargyl bromide and anhydrous potassium carbonate in dimethylformamide
(DMF) in order to synthesize terminal alkyne derivative required for its click reaction with
carboranyl azide. The reaction scheme is shown in Scheme 13 below.

Scheme 13:

Alkylation reaction of 3’, 5’-dihdroxyacetophenoneusing propargyl bromide
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CHAPTER 6
CLICK CHEMISTRY
Click chemistry was first invented by Nobel laureate K. Barry Sharpless in 1998. In
2001, Sharpless and his Scripps Research Institute colleagues Hartmuth and M.G Finn described
the concept in depth. The most popular concept of click chemistry lies within the Huisgen 1, 3dipolar cycloaddition of alkynes to azides to form 1, 4-disubstituted-1, 2, 3-triazoles using
cupper catalyst at room temperature28. Click chemistry had broad application most importantly in
the drug’s discovery. It is a very successful organic reaction in eliminating a complicated
tradition drug discovery process.
Click reaction is a simple, wide in scope and high yielding reaction between azide and
alkyne which was performed using Cu(I)I (copper (I) iodide) as a catalyst, and a 50:50 mixture
of acetonitrile (CH3CN) and tetrahydrofuran (THF) as solvent whereas N,Ndiisopropylethylamine (DIPEA) was used as a proton scavenger helping to avoid unwanted sidereactions. In this research work, click chemistry was used for attaching boron source in to the
various organic compounds. We have preferred Cu (I)-catalyzed reaction rather than Ru (II)catalyzed reaction because Cu (I) catalyst work effectively with terminal alkynes. If you have
alkyne and azide available, click reaction can be completed in a one-pot process so it is feasible
and quick reaction.
A general scheme of the click reaction is shown below in Scheme 14. Basically, it is a
cupper (I)-catalyzed union of compound containing azide functional group and terminal alkynes
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yielding a compound containing cyclic triazole ring. This reaction has succeeded so far in
making connections between structures that bear wide variety of functional groups; thus it is a
demanding approach applicable in this research.

Scheme 14:

A general scheme of click reaction

The proposed mechanism of click reaction is shown in scheme 16 below. The interesting
fact of the mechanistic scheme is that the regiospecific pathway of this mechanism is not limited
to azides, but also works well with nitrile oxides28. The barrier for this catalytic process has been
known to be considerable lower than one for the uncatalyzed reaction. The mechanism of click
reaction (Scheme 15) begins with the coordination of the alkyne to the Cu(I) species. Then the
alkyne is converted to the acetylide forming Cu acetylide species as bonafide intermediates. This
conversion process is believed to be involved in many C-C bond forming reactions. Now, azide
replaces one of the ligands and binds to the copper atom via the nitrogen proximal to carbon,
forming another intermediate. The distal nitrogen of the azide from this intermediate then attacks
the C-2 carbon of the acetylide, forming the unusual six-membered copper (III) metallacycle.
This process is known to be endothermic. The ring contraction of this metallacycle will from
triazolyl-copper derivative. It is calculated that the barrier for ring contraction is very low.
Finally, proteolysis of the triazolyl-copper derivative will give the desired triazole product. This
is how this catalytic cycle of click reaction is completed. It is also known that the rate
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acceleration of the cupper(I)-catalyzed process is enormous, 7 to 8 orders of magnitude, as
compared to the purely thermal cyclo-addition.

Scheme 15:

A proposed mechanism for click reaction [28]
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CHAPTER 7
SYNTHESIS OF CARBORANE-APPENDED BIOMOLECULES
In order to synthesize carborane-appended biomolecules, carboranyl azide was
synthesized first, and alkylation reaction was performed with the selected organic compounds to
synthesize organic compounds with terminal alkyne groups. Click chemistry was used to
incorporate azide into alkyne to give carborane-appended biomolecules. Click reaction was
carried out between alkynyl compounds (3, 4, 5, 6, 7, 8, 9 and 10) and carboranyl azide (2) to
give carborane-appended biomolecules as compound 11, 12, 13, 14, 15, 16, 17 and 18
respectively. All the details including their reaction schemes are discussed in the sections below.
Terminal alkyne containing 4-nitroimidazole derivative (Compound 3) was treated with
carboranyl azide compound (Compound 2) in order to attach them via click chemistry using
cupper catalyst to give carborane-appended compound 11 in good yield. The reaction scheme is
shown in scheme 16.
Terminal alkyne containing 2-nitroimidazole derivative (Compound 4) was treated with
carboranyl azide compound (Compound 2) in order to attach them via click chemistry using
cupper catalyst to give carborane-appended compound 12 in good yield. The reaction scheme is
shown in scheme 17.
Terminal alkyne containing phenothiazine derivative (Compound 5) was treated with
carboranyl azide compound (Compound 2) in order to attach them via click chemistry using
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cupper catalyst to give carborane-appended compound 13 in good yield. The reaction scheme is
shown in scheme 18.

Scheme 16:

Click reaction of 4-nitroimidazole derivative (3) with carboranyl azide (2)
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Scheme 17:

Click reaction of 2-nitroimidazole derivative (4) with carboranyl azide (2)
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Scheme 18:

Click reaction of phenothiazine derivative (5) with carboranyl azide (2)
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Terminal alkynes containing 1, 3, 4-thiadiazole-2, 5-dithiolderivative (Compound 6) was
treated with carboranyl azide compound (Compound 2) in order to attach them via click
chemistry using cupper catalyst to give carborane-appended compound 14 in good yield. This is
the first compound which contains two carboranes thus doubling the boron content. The reaction
scheme is shown in Scheme 19.

Scheme 19:
azide (2)

Click reaction of 1, 3, 4-thiadiazole-2, 5-dithiol derivative (6) with carboranyl
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Terminal alkynes containing adenine derivative (Compound 7) was treated with
carboranyl azide compound (Compound 2) in order to attach them via click chemistry using
cupper catalyst to give carborane-appended compound 15 in good yield. The reaction scheme is
shown in Scheme 20.

Scheme 20:

Click reaction of adenine derivative (7) with carboranyl azide (2)
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Terminal alkynes containing guanine derivative (Compound 8) was treated with
carboranyl azide compound (Compound 2) in order to attach them via click chemistry using
cupper catalyst to give carborane-appended compound 16. This is another compound which
contains two carboranes hence doubling the boron content. However; this reaction was not as
successful as we have expected. The reaction scheme is shown in Scheme 21.

Scheme 21:

Click reaction of guanine derivative (8) with carboranyl azide (2)
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Terminal alkynes containing 6-chloropurinederivative (Compound 9) was treated with
carboranyl azide compound (Compound 2) in order to attach them via click chemistry using
cupper catalyst to give carborane-appended compound 17 in good yield. The reaction scheme is
shown in Scheme 22.

Scheme 22:

Click reaction of 6-chloropurine derivative (9) with carboranyl azide (2)

39
Terminal alkynes containing 3’, 5’-dihydroxyacetophenonederivative (Compound 10)
was treated with carboranyl azide compound (Compound 2) in order to attach them via click
chemistry using cupper catalyst to give carborane-appended compound 18 in good yield. Again,
this is one of the compounds which contain two carboranes hence doubling the boron content.
The reaction scheme is shown in Scheme 23.

Scheme 23:
azide (2)

Click reaction of 3’, 5’-dihydroxyacetophenone derivative (10) with carboranyl
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Overall, click chemistry was used in order to synthesize the carborane-appended
derivative of the entire selected starting compound. We were successful in most of the
compounds except for guanine. Compound 11-18 were mostly characterized by NMR (1H, 13C,
11

B) and some of them by either FTIR or MS (see Appendix). In addition, elemental analysis was

also performed with some of the compounds in order to check their purity (see Chapter 10).
Moreover, carborane-appended compounds of coumarin derivatives were also synthesized using
the same approach which is discussed in chapter 8.
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CHAPTER 8
COUMARINS
8.1 Introduction
Coumarin belongs to the benzopyrone group of organic compounds and is widely found
in nature. This class of chemical compound has been generally used as fragrance, usually in
perfumes and fabric conditioners. They are also useful in diverse biological activities. Coumarin
was first synthesized in 1868, and since then it has been used as a precursor reagent in various
syntheses such as the anticoagulant warfarin by pharmaceutical industries29. It is therefore,
various coumarins derivatives have intrigued medicinal chemists for their applicability as drugs.

8.2 Coumarin Derivatives
It is known that coumarin derivatives are applicable in various therapeutics such as CNS
stimulants, anti-coagulants and antitumor29. Therefore, it is desired to synthesize coumarin
derivatives and attach polyhedral carborane cage into it for BNCT application. The coumarin
derivatives we have synthesized are bio-compatibles and easy to functionalize. We have used
commercially available resorcinol as our starting material and treated them with ethyl-2ethylacetoacetate or ethylacetoacetate to yield coumarin derivatives compounds 19 and 22
respectively. The reaction schemes are shown in Scheme 24 and Scheme 25 respectively.
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Scheme 24:

Synthesis of coumarin derivative using ethyl-2-ethylacetoacetate

Scheme 25:

Synthesis of coumarin derivative using ethylacetoacetate

8.3 Alkylation Reactions
Thus derived coumarins derivatives (19 and 22) were treated with propargyl bromide and
anhydrous potassium carbonate to synthesize compound 20 and 23 respectively as an alkyne
source for click reaction. The general scheme of the alkylation reaction is shown in Scheme 26
and Scheme 27.
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Scheme 26:

Alkylation of coumarin derivative (19) using propargyl bromide

Scheme 27:

Alkylation of coumarin derivative (22) using propargyl bromide

8.4 Click Reactions
In order to attach the boron source (Compound 2) onto the alkylated derivatives of
coumarins (Compounds 20 and 23), a click reaction was performed using Cu(I) catalyst for three
days at room temperature to yield compound 21 and 24 respectively. The cytotoxicity of these
compounds have been tested and both of them are found to be non-toxic. The general scheme of
the click reactions performed is shown in Scheme 28 and Scheme 29 respectively.
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Scheme 28:

Click reaction of alkylated coumarin derivative (20) with carboranyl azide (2)
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Scheme 29:

Click reaction of alkylated coumarin derivative (23) with carboranyl azide (2)

Again, click chemistry was used in order to synthesize the carborane-appended
derivatives of the coumarins. Compounds 21 and 24 were characterized by NMR (1H, 13C, 11B)
(see Appendix).
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8.5 Cytotoxicity
Cytotoxicity study of compounds 21 and 24 were carried out in a triple negative breast
cancer cell line MDA-MB-231 (Credit: Shirisha Gurrapu, University of Minnesota Duluth). The
compounds were dissolved in DMSO and IC50 was tested starting from 100 µM to 0.78 µM. The
IC50 values of both compounds are greater than 100 µM confirming that the compounds are nontoxic. The data analysis was performed by using GraphPad Prism 6 software which is shown in
Figure 9 and Figure 10 below. Both compounds (21 and 24) were tested three times for their
consistency (only one shown). The procedure of the experiment is discussed in Experimental
section (Chapter 10). This will lead to the bio-distribution studies of these compounds.

Figure 9:

Cytotoxicity result of Compound 21 (IC50 >100 µM)
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Figure 10:

Cytotoxicity result of Compound 24 (IC50 >100 µM)

48

CHAPTER 9
WATER SOLUBILITY

Firstly, making the synthesized compounds water soluble is one of the critical
requirements to be fulfilled before transporting them into the body. It is a priority to make all the
synthesized compounds water soluble by decapitation of the carborane cage in order to perform
their biological evaluation. To make these compounds water soluble, several reactions have been
performed in order to investigate and optimize their reaction conditions. This work is currently
under way as well.
The reaction scheme of decapitating the carborane cage of compound 11 is shown in
Scheme 30 below.
Similarly, the reaction scheme of decapitating the carborane cage of compound 14 is
shown in Scheme 31 below.
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11

25

Scheme 30:

Decapitation of carborane-appended 4-nitroimidazole compound (11)
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14

26

Scheme 31:

Decapitation of carborane-appended 1, 3, 4-thiadiazole-2, 5-dithiol derivative

(compound 11)

The Water Solubility table of decapitated compounds (25 and 26) along with their
comparison to carborane-appended compounds (11 and 14) is shown in Table 3 below. The
experiment was started with dissolving 0.1 mg of compound 11 in 10 mL of deionized water and
while increasing the mass gradually it was found that 0.17 mg of compound 11 dissolved
completely in 10 mL of deionized water. When the mass of compound 11 was at 0.2 mg, it was
observed that the compound 11 did not dissolve completely, thus providing the evidence that the
solubility limit is 0.17mg/10 mL (0.017mg/1mL or 42 µM).
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Table 3
Solubility (µM) table of decapitated compounds
Compound
#

Molecular Weight
(g/mol)

Solubility
(µM)

11

406.38

42

25

527.58

378

14

736.98

55

26

752.54

531

The solution was kept in ultra-sonication bath for half hour. Likewise, 1 mg of compound 25 was
treated with 10 mL of deionized water, and upon gradual increase in the mass it was found that 2
mg of compound 25 dissolves completely in 10 mL of deionized water. When the mass of
compound 25 was at 2.5 mg, it was observed that the compound 25 did not dissolve completely.
Therefore, it is known that maximum solubility limit of compound 25 is 2mg/10mL (0.2mg/1mL
or 378 µM). This solution was also kept in ultra-sonication bath for half hour. Again, another
experiment was started with dissolving 0.1 mg of compound 14 in 10 mL of deionized water and
while increasing the mass gradually it was found that 0.4 mg of compound 11 dissolved
completely in 10 mL of deionized water. When the mass of compound 14 was at 0.45 mg, it was
observed that the compound 14 did not dissolve completely. Thus, it is known that maximum
solubility limit of compound 14 is 0.4mg/10mL (0.040mg/1mL or 55 µM).

52
The solution was kept in ultra-sonication bath for half hour. Likewise, 1 mg of compound 26 was
treated with 10 mL of deionized water, and upon gradual increase in the mass it was found that 5
mg of compound 26 dissolves completely in 10 mL of deionized water. When the mass of
compound 26 was at 5.5 mg, it was observed that the compound 26 did not dissolve completely.
Therefore, it is known that maximum solubility limit of compound 26 is 5mg/10mL (0.5mg/1mL
or 531 µM). The solution was kept in ultra-sonication bath for half hour.
Overall, the solubility of decapitated compounds was tested by dissolving them in
deionized water and visually observing them. The calculated solubility (µM) has proven that the
solubility of the compounds 11 and 14 were increased by almost 10 folds after the decapitation.
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CHAPTER 10
EXPERIMENTAL
All reactions were generally performed under argon atmosphere in an oven-dried flask
using standard Schlenk techniques. Solvents and reagents were added by syringes as required.
All solvents were dried using standard procedure. Reagents were used as purchased without
further purification unless indicated otherwise. The progresses of all reactions were monitored
using thin layer chromatography (TLC). All the products synthesized were purified by column
chromatography on silica gel (70-230 mesh). Compounds 5 and 13 were purified by adding a
drop of triethyl amine (TEA) or ammonium hydroxide (NH4OH) in the silica while silica was
degrading the compound. Both 1H NMR and 13C NMR were recorded on a burker NMR
spectrometer at 300 MHz frequency. The chemical shifts were reported relative to CDCl3(1H: ∂=
7.24 ppm, 13C: ∂= 77.23 ppm), CD3CN (1H: ∂= 1.94 ppm, 13C: ∂= 118.69, 1.39 ppm) and DMSO
(1H: ∂= 2.50(5) ppm, 13C: ∂= 39.51 (7)). The 11B NMR spectra were also recorded at 300 MHz.
On the other hand, infrared (IR) spectra of compounds 11, 12, 13 and 14 were recorded on an
ATR FT-IR Spectrophotometer. All the compounds were completely dried under high vacuum.
Mass spectral analyses of compounds 11, 12, 13 and 14 shown were performed in UIUC using
high resolution mass spectrometry.
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The reaction scheme (Scheme 4) is started with 3.17g (20.00 mmol) of 1-methyl-ocarborane (C3H14B10) in an oven-dried 250-mL round-bottom, three-necked flask equipped with
a magnetic stirring bar and the compound was dissolved in 100 mL of a diethyl ether/ toluene
(v/v=2/1). The reaction mixture was then cooled to -78 °C using dry ice, and then 12.6 mL
(20.16 mmol) of the tert-butyllithium was added drop-wise to the mixture with the help of a
syringe. The mixture was maintained at -78 °C for nearly 30 min and then allowed slowly to
warm to room temperature. The reaction mixture was stirred at room temperature for 4 hours and
cooled to 0 °C using ice. Approximately 3.0 mL (22.75 mmol) of 1,4-diiodobutane was added to
the mixture using a syringe, and the reaction mixture was stirred for 30 min at 0 °C, slowly
warmed to room temperature, stirred for additional 2 hours and then refluxed for nearly 4 hours.
After reflux was done, the mixture was cooled to 0 °C and then quenched with deionized (DI)
water. Solvents were evaporated using a rotary evaporator, and the extraction was carried out
using diethyl ether and DI H2O. All the extracts from aqueous layer were combined with organic
layer, and then solvents were removed, yielding 2.8 g (82% yield) of yellow sticky residue,
compound 1. The purity of compound 1 was monitored with TLC, developed with nhexane/ethyl acetate (v/v=6/1) and purified using silica-gel column chromatography.
2.00 g (5.88 mmol) of compound 1 was mixed with 3.90 g (59.39 mmol) of sodium azide
and 120 mL of anhydrous acetone and refluxed in the dark for 3 days in a 250-mL round-bottom
flask equipped with a magnetic stirring bar. After 3 days, the reaction mixture was cooled to
room temperature, solvents were removed using a rotary evaporator and the residue was
extracted using diethyl ether. The diethyl ether was then removed from the extract to give the
crude product that was later purified by TLC (SiO2, developed with n-hexane/ethyl acetate in 5:1
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ratio) and silica-gel column chromatography to yield 1.35 g (90% yield) of compound 2 as waxy,
pale yellow solid. Compounds 1 and 2 were characterized by NMR (1H, 13C, 11B) and FTIR (see
Appendix).
Compounds 3, 4, 5, 6, 7, 8, 9 and 10 were synthesized by treating the commercially
available organic compounds (4-nitroimidazole, 2-nitroimidazole, phenothiazine and 1,3,4thiadiazole-2,5-dithiol, adenine, guanine, 6-chloropurine and 3’,5’-dihydroxyacetophenone)
individually with propargyl bromide in presence of strong base potassium carbonate or
potassium tert-butoxide (K2CO3/KOtBu) and dry solvent acetone/acetonitrile or N,N
dimethylformamide (DMF) in a 100 mL round bottom flask equipped with magnetic stirring bar
(see Schemes 6-13).
Compound 3 was synthesized by treating 340 mg (3.007 mmol) of commercially
available 4-nitroimidazole with 435 mg (3.148 mmol) of anhydrous K2CO3 using 10 mL of dry
acetone under argon atmosphere using schlenk lines. Approximately 0.4 mL of propargyl
bromide was added to the reaction mixture using a syringe, and the reaction was stirred overnight
at room temperature. The reaction mixture was diluted with 10 mL of ethyl acetate, products
were filtered and solvent was removed to collect white solid powder-like product. The purity of
compound 3 was monitored with thin-layer chromatography, developed with n-hexane/ethyl
acetate (v/v=1/1) and purified using silica-gel column chromatography yielding 400 mg (2.65
mmol), 88% yield of the product. The identification of this compound was confirmed by
characterization with 1H and 13C NMR (see Appendix).
Similarly, compound 4 was synthesized by treating 100 mg (0.88 mmol) of commercially
available 2-nitro imidazole with 140 mg (1.013 mmol) of anhydrous K2CO3 using 10 mL of dry
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acetone under argon atmosphere using schlenk lines. Approximately 0.2 mL of propargyl
bromide was added to the reaction mixture using syringe, and reaction was stirred overnight at
room temperature. The reaction mixture was then diluted with 10 mL of ethyl acetate, products
were filtered and solvent was removed to collect yellowish sticky residue that solidifies upon
standing. The purity of compound 4 was monitored with thin-layer chromatography, developed
with n-hexane/ethyl acetate (v/v=1/1) and purified using silica-gel column chromatography
yielding 95 mg (0.63 mmol), 70% yield of the product. The identification of this compound was
confirmed by characterization with 1H and 13C NMR (see Appendix).
Similarly, compound 5 was synthesized by treating 500 mg (2.51 mmol) of commercially
available phenothiazine with 470 mg (3.40 mmol) of anhydrous K2CO3 using 25 mL of dry
acetonitrile under argon atmosphere using schlenk lines. Approximately 3.4 mL of propargyl
bromide was added to the reaction mixture using syringe and reaction was stirred overnight at
room temperature. Solvents were evaporated using a rotary evaporator, and the extraction was
carried out using dichloromethane (DCM) and DI H2O. Firstly, organic layer was separated and
the aqueous layer was extracted with dichloromethane (3× 50 mL). All the extracts from the
aqueous layer were combined with the organic layer, and then solvents were removed. The purity
of compound 5 was monitored with thin-layer chromatography, developed with n-hexane/ethyl
acetate (v/v=1/1) and purified using silica-gel column chromatography, yielding 620 mg (2.74
mmol), 80% yield of brown solid powder as a product25. The identification of compound was
confirmed by characterization with 1H and 13C NMR (see Appendix).
Similarly, compound 6 was synthesized by treating 500 mg (3.327 mmol) of
commercially available 1,3,4-thiadiazole-2,5-dithiol with 750 mg (6.684 mmol) with anhydrous
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KOtBu using 15 mL of dry acetonitrile under argon atmosphere using Schlenk lines.
Approximately 0.4 mL of propargyl bromide was added to the reaction mixture using a syringe,
and reaction was stirred overnight at room temperature. Solvents were evaporated using a rotary
evaporator and the extraction was carried out using diethyl ether and milli-Q H2O. Firstly,
organic layer was separated and the aqueous layer was extracted with diethyl ether (3× 50 mL).
All the extracts from the aqueous layer were combined with the organic layer, and then solvents
were removed. The purity of compound 6 was monitored with thin-layer chromatography,
developed with n-hexane/ethyl acetate (v/v=1/1) and purified using silica-gel column
chromatography, yielding 680 mg (2.87 mmol), 86% yield of brown solid powder as a product.
The identification of compound was confirmed by characterization with 1H and 13C NMR (see
Appendix).
Compound 7 was synthesized by treating 100 mg (0.74 mmol) of commercially available
adenine with 102.3 mg (0.74 mmol) of anhydrous potassium carbonate and 0.1 mL of propargyl
bromide while dissolving in 25 mL of DMF. The reaction mixture was refluxed overnight.
Solvents were removed, and then extraction was performed using 30 mL DI water and ethyl
acetate. The residue was washed with water and dried under sodium sulfate. The purification was
done by column chromatography developed in 30% hexane and 70% ethyl acetate. The product
was dried under high-vacuum for 3 days to give compound 7 in 65% yields as white powder.
Compound 7 was characterized by doing 1H and 13C NMR using 300 MHZ Burker NMR (see
Appendix).
Similarly, compound 8 was synthesized by treating 100 mg (0.66 mmol) of commercially
available guanine with 182mg (1.32 mmol) of anhydrous potassium carbonate and 0.15 mL of
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propargyl bromide while dissolving in 25 mL of DMF. The reaction mixture was refluxed
overnight. Solvents were removed, and then extraction was performed using 30 mL DI water and
ethyl acetate. The residue was washed with water and dried under sodium sulfate. The
purification was done by column chromatography developed in 10% hexane and 90% ethyl
acetate. The product was dried under high-vacuum for 3 days to give compound 8 in 60% yields
as brownish powder. Compound 8 was characterized by doing 1H and 13C NMR using 300 MHZ
Burker NMR (see Appendix).
Compound 9 was synthesized by treating 200 mg (1.3 mmol) of 6-chloropurine with 180
mg (1.3 mmol) of anhydrous potassium carbonate and 0.1 mL of propargyl bromide in 10 mL
dry DMF . Two separate reactions were performed at the same time, one at room temperature
and the other at reflux for 24 hrs. Extraction was carried out using 20 mL DI water and ethyl
acetate. Two spots were observed in thin layer chromatography, so prep TLC was done to
separate them. Column chromatography was also performed for further purification using 30%
hexane and 70% ethyl acetate. The residue was dried under high-vacuum to give compound 9 in
85% yields as a dark brown crystalline powder. The results from the reaction performed at RT
were better while compared to one with reflux. Compound 9 was characterized by doing 1H and
13

C NMR using 300 MHZ Burker NMR (see Appendix).
Likewise, compound 10 was synthesized by treating 200 mg (1.31 mmol) of 3’,5’-

dihydroxyacetophenone with 362 mg (2.62 mmol) of anhydrous potassium carbonate and 0.25
mL of propargyl bromide in 20 mL dry DMF. The reaction mixture was stirred at RT for 24
hours, and then solvents were evaporated under reduced pressure. Extraction was carried out
using 40 mL DI water and diethyl ether (3 folds). All the organic phases were combined and
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evaporated, and then washed with water and dried over anhydrous sodium sulfate. Compound 10
was also purified by doing silica gel column chromatography developed in 40% hexane and 60%
ethyl acetate. The residue obtained was dried under high- vacuum for 3 days to give compound
10 in 80% yields as brownish-yellow crystalline substance (see Appendix).

Click reaction was carried out between alkynyl compounds (3, 4, 5, 6, 7, 8, 9 and 10) and
carboranyl azide (Compound 2) to give carborane-appended compounds (11, 12, 13, 14, 15, 16,
17 and 18) respectively (see scheme 16-23).
Compound 11 (C13H26N6B10O2) was synthesized by treating 300 mg (1.985 mmol) of
compound 3 with 255 mg (1.00 mmol) of compound 2 using 10 mL dry acetonitrile/THF (v/v =
1/1) and under argon atmosphere using schlenk lines. Approximately 210 mg (1.10 mmol) of
Cu(I)I was added to the reaction mixture as a catalyst and 2 mL (10 mmol) of DIPEA was also
added in the mixture. Click reaction was carried out by stirring the reaction mixture at room
temperature for 3 days. Solvents were evaporated using a rotary evaporator. The purity of
compound 11 was monitored with TLC, developed with n-hexane/ethyl acetate (v/v=1/2) and
purified using silica-gel column chromatography, yielding 345 mg (0.85 mmol), 85% yield of
dark-brown solid powder as a product. The identification of this compound was confirmed by
characterization with NMR (1H, 13C and 11B), FTIR, MS and elemental analysis (see Appendix).
Elemental analysis calculated for C13H26N6B10O2C 38.7%, H 6.4%, N 20.6%; found C
38.8%, H 6.2% N 20.3%.
Similarly, compound 12 ( C13H26N6B10O2) was synthesized by treating 80 mg (0.53
mmol) of compound 4 with 65 mg ( 0.26 mmol) of compound 2 using 5 mL dry CH3CN/THF
(v/v = 1/1) under argon atmosphere using schlenk lines. Approximately 55 mg (0.29 mmol) of
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Cu(I)I was added to the reaction mixture as a catalyst, and 0.5 mL (2.5 mmol) of DIPEA was
also added in the mixture. Click reaction was carried out by stirring the reaction mixture at room
temperature for 3 days. Solvents were evaporated using a rotary evaporator. The purity of
compound 12 was monitored with TLC, developed with n-hexane/ethyl acetate (v/v=1/2) and
purified using silica-gel column chromatography, yielding 90 mg (0.22 mmol), 86% yield of pale
brown, solid powder as a product. The identification of this compound was confirmed by
characterization with NMR (1H, 13C and 11B), FTIR, MS and elemental analysis (see Appendix).
Elemental analysis calculated for C13H26N6B10O2C 38.7%, H 6.4%, N 20.6%; found C
37.96%, H 6.35% N 20.2%.
Similarly, compound 13 (C22H30N4B10S) was synthesized by treating 250 mg (1.053
mmol) of compound 5 with 128 mg ( 0.501 mmol) of compound 2 using 8 mL dry CH3CN/THF
(v/v = 1/1) under argon atmosphere using schlenk lines. Approximately 105 mg (0.55 mmol) of
Cu(I)I was added to the reaction mixture as a catalyst, and 0.9 mL (5.02 mmol) of DIPEA was
also added in the mixture. Click reaction was carried out by stirring the reaction mixture at room
temperature for 3 days. Solvents were evaporated using a rotary evaporator. The purity of
compound 13 was monitored with TLC, developed with n-hexane/ethyl acetate (v/v=1/2) and
purified using silica-gel column chromatography, yielding 220 mg (0.449 mmol), 90% yield of
pale black, solid powder as a product. The identification of compound was confirmed by
characterization with NMR (1H, 13C and 11B), FTIR, MS and elemental analysis (see Appendix).
Elemental analysis calculated for C22H30N4B10S C 53.8%, H 6.16%, N 11.5%; found C
58.13%, H 7.43% N 11.73%.
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Similarly, compound 14 ( C22H48N4B10S3) was synthesized by treating 245 mg (1.082
mmol) of compound 6 with 277 mg ( 1.083 mmol) of compound 2 using 10 mL dry CH3CN/THF
(v/v = 1/1) under argon atmosphere using schlenk lines. Approximately 230 mg (1.207 mmol) of
Cu(I)I was added to the reaction mixture as a catalyst, and 1.9 mL (10.83 mmol) of DIPEA was
also added in the mixture. Click reaction was carried out by stirring the reaction mixture at room
temperature for 3 days. Solvents were evaporated using a rotary evaporator. The purity of
compound 14 was also monitored with TLC, developed with n-hexane/ethyl acetate (v/v=1/2)
and purified using silica-gel column chromatography, yielding 705 mg (0.957 mmol), 88% yield
of bright brown powder as a product. The identification of this compound was confirmed by
characterization with NMR (1H, 13C and 11B), FTIR, ESI-TOF MS and elemental analysis (see
Appendix).
Elemental analysis calculated for C22H48N4B10S3 C 36%, H 6.5%, N 15.2%; found C
36.8%, H 6.1% N 17.3%.
Compound 15 (C15H28N8B10) was synthesized by treating 100 mg (0.577 mmol) of
compound 7 with 150 mg (0.577mmol) of compound 2 using 20 mL dry CH3CN/THF (v/v =
1/1) under argon atmosphere using schlenk lines. Approximately 120 mg (0.627mmol) of Cu(I)I
was added to the reaction mixture as a catalyst, and 1 mL (5.77 mmol) of DIPEA was also added
in the mixture. Click reaction was carried out by stirring the reaction mixture at room
temperature for 3 days. Solvents were evaporated using a rotary evaporator. The purity of
compound 15 was monitored with TLC, developed with n-hexane/ethyl acetate (v/v=1/2) and
purified using silica-gel column chromatography, yielding 75% yield of dark brownpowder as a
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product. The identification of compound was confirmed by characterization with NMR (1H, 13C
and 11B) and elemental analysis (see Appendix).
Elemental analysis calculated for C15H28N8B10 C 42%, H 6.59%, N 26.13%; found C 44.33%, H
7.19% N 27.76%.
Similarly, compound 16 (C25H51N11B20) was synthesized by treating 200 mg (0.88 mmol)
of compound 8 with 450 mg (1.76mmol) of compound 2 using 40 mL dry CH3CN /THF (v/v =
1/1) under argon atmosphere using schlenk lines. Approximately 185 mg (0.968 mmol) of Cu
(I)I was added to the reaction mixture as a catalyst, and 1.53 mL (8.8 mmol) of DIPEA was also
added in the mixture. Click reaction was carried out by stirring the reaction mixture at room
temperature for 3 days. Solvents were evaporated using a rotary evaporator. The purity of
compound 16 was monitored with TLC, developed with n-hexane/ethyl acetate (v/v=1/2) and
purified using silica-gel column chromatography, yielding 68% yield of dark brown powder as a
product. The identification of compound was confirmed by characterization with NMR (1H, 13C
and 11B). However, NMR results were not accurate to confirm the identity of compound 16.
Compound 17 (C15H26N7B10Cl) was synthesized by treating 90 mg (0.47 mmol) of
compound 9 with 120 mg (0.47 mmol) of compound 2 using 40 mL dry CH3CN /THF (v/v =
1/1) under argon atmosphere using schlenk lines. Approximately 100 mg (0.517 mmol) of Cu (I)
I was added to the reaction mixture as a catalyst, and 1 mL (4.7 mmol) of DIPEA was also added
in the mixture. Click reaction was carried out by stirring the reaction mixture at room
temperature for 3 days. Solvents were evaporated using a rotary evaporator. Extraction was
performed with 40 mL of DI water and diethyl ether. The purity of compound 17 was checked
with TLC, developed with n-hexane/ethyl acetate (v/v=1/2) and purified using silica-gel column
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chromatography, yielding 84% yield of white solid as a product. The identification of compound
was confirmed by characterization with NMR (1H, 13C and 11B) and elemental analysis (see
Appendix).
Elemental analysis calculated for C15H26N7B10Cl C 43.6%, H 6.35%, N 23.75%; found C
39.8%, H 6.4% N 24.3%.
Compound 18 (C28H54B20O3) was synthesized by treating 100 mg (0.44 mmol) of
compound 10 with 225 mg (0.88 mmol) of compound 2 using 40 mL dry CH3CN/THF (v/v =
1/1) under argon atmosphere using schlenk lines. Approximately 92 mg (0.484 mmol) of Cu (I) I
was added to the reaction mixture as a catalyst, and 0.8 mL (4.4 mmol) of DIPEA was also
added in the mixture. Click reaction was carried out by stirring the reaction mixture at room
temperature for 3 days. Extraction was performed with 50 mL of DI water and diethyl ether. The
purity of compound 18 was also checked with TLC, developed with n-hexane/ethyl acetate
(v/v=1/2) and purified using silica-gel column chromatography, to give 78% yield of a brown
solid as a product. The identification of compound was confirmed by characterization with
NMR (1H, 13C and 11B) and elemental analysis (see Appendix).
Elemental analysis calculated for C28H54B20O3 C 51.3%, H 8.2%; found C 51.8%, H
8.4%.
Compound 19 (C12H12O3) was synthesized by treating 1g (9.08 mmol) of commercially
available Resorcinol with 1.2 equivalents (1.76 mL) of ethyl-2-ethylacetoacetate and 5 mL of dry
acetone, and 5 mL of concentrated H2SO4was added drop-wise, while stirring the reaction
mixture at RT for 3 hours (see Scheme 24). The progress of the reaction was monitored using
thin- layer chromatography using 5% methanol in 95% chloroform. TLC showed a single spot,
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so the product was cooled using ice and sonication was done for 30 minute. The reaction mixture
was filtered and residue was collected and kept under high-vacuum overnight yielding a dry
white crystalline solid in 90% percent yield. The identity of compound 19 was confirmed by
performing 1H and 13C NMR using DMSO (see Appendix).
To a solution of 1g (4.9 mmol) coumarins (compound 19) in dry acetone (10mL), 1.5
equivalent of anhydrous potassium carbonate (7.4 mmol), and 1.2 mL propargyl bromide (7.4
mmol) were added (see Scheme 25). The resultant mixture was stirred and refluxed at 60 °C for
24 hours, then the mixture was cooled and filtered, and the solvent was evaporated under
reduced pressure using a rotary evaporator. The residue was then treated with 20 mL of
deionized water and extracted with ethyl acetate. All organic phase extracts were combined,
washed with DI water, dried over anhydrous magnesium sulfate and then filtered. The obtained
crude product was purified by crystallization from hexane/ethyl acetate mixture to give
compound 20 (C15H14O3) in 80% yield. The identity of compound 20 was confirmed by
performing 1H and 13C NMR using DMSO (see Appendix).
Compound 21 (C22H35N3B10O3) was synthesized by treating 200 mg (0.82 mmol) of
compound 20 with 210 mg ( 0.82 mmol) of compound 2 using 15 mL dry CH3CN/THF (v/v =
1/1) under argon atmosphere using schlenk lines (see Scheme 26). Approximately 172 mg
(0.902mmol) of Cu(I)I was added to the reaction mixture as a catalyst, and 1.43mL (8.2mmol) of
DIPEA was also added in the mixture as a proton scavenger. The reaction mixture was stirred at
room temperature for 3 days. The progress of the reaction was frequently monitored with TLC.
Extraction was performed using 20 mL of DI water and ethyl acetoacetate. Solvents were
evaporated using a rotary evaporator. Initially, recrystallization using hexane and ethyl acetate
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was performed for the purification of compound 21; however,it was unsuccessful. Therefore,
silica-gel column chromatography developed with n-hexane/ethyl acetate (v/v=1/2) was
performed for further purification, yielding 82% of bright brownish powder as a product. The
identification of compound was confirmed by characterization with NMR (1H, 13C N and 11B)
(see Appendix).
Compound 22 (C10H8O3) was synthesized by treating 1g (9.08 mmol) of commercially
available Resorcinol with 1.2 equivalent (10.9 mmol, 1.4 mL) of ethyl acetoacetate and 5 mL of
dry acetone, and 5 mL of concentrated H2SO4was added drop-wise while stirring the reaction
mixture at 60 °C for 2 hours (see Scheme 27). The progress of the reaction was monitored using
thin layer chromatography using 5% methanol in 95% chloroform. TLC showed a single spot, so
the product was cooled using ice and sonication was done for 30 min. The reaction mixture was
filtered and residue was collected and kept under high-vacuum overnight yielding a dry brown
crystalline solid in 90% yield. The identity of compound 22 was confirmed by performing 1H
and 13C NMR using DMSO (see Appendix).
To a solution of 1g (5.7mmol) coumarins (compound 22) in dry acetone (10mL), 1.5
equivalent of anhydrous potassium carbonate (8.5 mmol), and 1.4 mL propargyl bromide (8.5
mmol) were added (see Scheme 28). The resultant mixture was stirred and refluxed at 70 °C
overnight, then the mixture was cooled and filtered, and the solvent was evaporated under
reduced pressure. The residue was then treated with 20 mL of deionized water and extracted with
ethyl acetate. All organic phase extracts were combined, washed with DI water, dried over
anhydrous magnesium sulfate and filtered. The obtained crude product was purified by
recrystallization using hexane and ethyl acetate to give compound 23 (C13H10O3) in 85% yields.
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The identity of compound 23 was confirmed by performing 1H and 13C NMR using DMSO (see
Appendix).
Compound 24 (C20H31N3B10O3) was synthesized by treating 300 mg (1.4mmol) of
compound 23 with 358 mg ( 1.4mmol) of compound 2 using 40 mL dry CH3CN/THF (v/v = 1/1)
and under argon atmosphere using Schlenk lines (see Scheme 29). Approximately 295 mg
(1.55mmol) of Cu(I)I was added to the reaction mixture as a catalyst and 2.5 mL (15mmol) of
DIPEA was also added in the mixture to help avoid unwanted reactions. The reaction mixture
was stirred at room temperature for 3 days. The reaction’s reaction was frequently monitored
with thin layer chromatography. Extraction was performed using 40 mL of DI water and ethyl
acetoacetate. Solvents were evaporated using rotary evaporator. The purity of compound 24 was
successful with recrystallization using hexane and ethyl acetate, while further purification was
carried out by doing silica-gel column chromatography developed with n-hexane/ethyl acetate
(v/v=1/2), yielding 87% of white solid powder as a product. The identification of compound was
confirmed by characterization with NMR (1H, 13C N and 11B) (see Appendix).
Compounds 25 and 26 were synthesized by treating compounds 11 and 14 with a strong
base (NaOH, KOH and CsOH) and 95% ethanol or THF as a solvent, and refluxed the reaction
mixture for three days stirring under argon (see Schemes 30 and 31).
The first attempt was using NaOH as a base to decapitate the carborane cage. A solution
was prepared by dissolving 2g of NaOH in 60 mL of 95% ethanol, and the resulting solution was
then added to 60 mg of carborane-appended compound (11 or 14). The reaction mixture was
constantly stirred in an ultrasonic bath for approximately thirty minutes, and then heat was
applied to the resulting mixture, which was then refluxed for three days. The mixture was then
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cooled to 0°C, and the solution was neutralized with aqueous HCl to a pH of ~5.0 in order to
remove unreacted salts. The solution was slowly washed with cold water to remove NaCl, and
solvents were removed by rotary evaporator under reduced pressure. Then, the resulting
compound was dried under high vacuum. Extraction was performed using 20 mL of DI water
and DCM. The resulting residue was purified by doing column chromatography developed in
hexane and ethyl acetate. However, the outcome of characterization was not positive as
confirmed by NMR results, so other attempts were made using CsOH or KOH as a base.
Compound 25 was synthesized by treating 65 mg (0.16 mmol) of compound 11 with 50
mg (0.32 mmol) of CsOH (cesium hydroxide) in 10 mL of ethanol, while refluxing the mixture
for three days. The obtained crude mixture was cooled to 0 °C using ice and solvents were
evaporated under reduced pressure. The compound was extracted by using 20 mL DI water and
diethyl ether. Column chromatography was performed for compounds purification, by initially
washing with 100% hexane and then eluting with 60% ethyl acetate. Compound 25 was
characterized by 1H, 13C and 11B NMR (see Appendix).
Compound 26 was synthesized by treating 250 mg (0.34 mmol) of compound 14 with
381.5 mg (6.8 mmol) of potassium hydroxide in 5 mL of THF and 10 mL of ethanol, while
refluxing the mixture for 24 hours. The obtained reaction mixture was then cooled to RT, and
then cooled by using dry ice. The insoluble portion of the mixture was filtered through a Buchner
funnel, and then the filtrate was concentrated and dried under high vacuum. The compound was
purified by performing column chromatography developed in DCM and acetone, a separation
starting with 10% acetone and slowly increasing the concentration of acetone over time, acetone
being eluent in this case. The purity of compound was not confirmed, so recrystallization was

68
performed for further purification using water and ethanol. This compound was characterized by
1

H, 13C and 11B NMR (see Appendix).
In order to perform the cytotoxicity studies of the compounds 21 and 24 MDA-MB-231

culture media consists of DMEM, 10% FBS and 1% penicillin-streptomycin was used. Cells
were seeded at 5x10^4 cells/mL in 96-well plates and incubated at 37oC and 5% CO2 atmosphere
for 18-24 hours. The stock solutions of test compounds were prepared in DMSO at 1000x
concentration and further diluted in growth media. 100µL of this solution was added into 96-well
plate in replicate and serial dilution was done. The plated were incubated for 72 hours and 10µL
of MTT (5mg of MTT in 1mL of 1X PBS) was added in each well and incubated for 4 hours.
100µL of SDS-HCl (1g SDS in 10 mL 0.01N HCl) was added into wells to dissolve formazan
precipitate and further incubated for 4 hours. Absorbance was recorded at 570 nm and % survival
was calculated using growth media as control [%survival = (absorbance of test
compound/absorbance of control)*100].
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CHAPTER 11
SUMMARY OF RESULTS
All the compounds were isolated in good yield. All the compounds were assigned their
number for their easy identification purpose starting from 1 to 26. Their respective molecular
formula, molecular weight and percent yields are shown in the Tables 4-8 below.
Table 4
Summary of results for compounds 1 and 2 (Carboranes)
Compound #

Molecular Formula

Molecular Weight
(g/mol)

% Yield

1

C7H21B10I

340.26

82

2

C7H21B10N3

255.37

90

Table 5
Summary of results for compounds 3 to 10 (Alkynyl Derivatives)
Compound #

Molecular Formula

Molecular Weight
(g/mol)

% Yield

3

C6 H5N3O2

151.12

88

4

C6H5N3O2

151.12

70

5

C15H11NS

237.32

80

6

C8H6N2S3

226.34

86

7

C8H7N5

173.2

65

8

C11H9N5O

227.2

60

9

C8H5N4Cl

192.6

85

10

C14H12O3

228.2

80
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Table 6
Summary of results for compounds 11to 18 (Carborane-Appended Biomolecules)
Compound
#

Molecular Formula

Molecular Weight
(g/mol)

% Yield

11

C13H26N6B10O2

406.378

90

12

C13H26N6B10O2

406.378

95

13

C22H30N4B10S

490.675

70

14

C22H48N8B20S3

736.982

80

15

C15H28N8B10

428.55

75

16

C25H51N11B20

721.96

68

17

C15H26N7B10Cl

540

84

18

C28H54B20O3

654.94

78

Table 7
Summary of results for compounds 19 to 24 (Coumarins Derivatives)
Compound
#
19

C12H12O3

Molecular Weight
(g/mol)
204.22

20

C15H14O3

242.27

80

21

C22H35N3B10O3

497.64

82

22

C10H8O3

176.17

90

23

C13H10O3

214.22

85

24

C20H31N3B10O3

469.59

87

Molecular Formula

% Yield
90

71
Table 8
Summary of results for compounds 25 and 26 (Decapitated Compounds)
Compound
#

Molecular Formula

Molecular Weight
(g/mol)

% Yield

25

C13H25N6B9O2Cs

527.58

70

26

C22H46N8B18S3K

752.54

75
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CHAPTER 12
DISCUSSION AND CONCLUSIONS
When commercially available organic compounds; 4-nitroimidazole, 2-nitroimidazole,
phenothiazine, 1,3,4-thiadiazole-2,5-dithiol, adenine, guanine, 6-chloropurine and 3’,5’dihydroxyacetophenone were treated with propargyl bromide in the presence of strong base
K2CO3 or KOtBu and dry acetone/acetonitrile or DMF/THF as solvent, compounds 3, 4, 5, 6,
7 ,8, 9 and 10 were obtained in quantitative yield (see Schemes 6-13). Likewise, carboranyl
azide (compound 2) was synthesized in a good yield following the protocol mentioned in the
literature procedure2 (see Scheme 4). Compounds 11, 12, 13, 14, 15, 16, 17 and 18 (see Schemes
16-23) were synthesized by the reaction between carboranyl azide (compound 2) and compounds
3, 4, 5, 6, 7, 8, 9 and 10 respectively via click reactions. Similarly, compounds 19 and 22 are
synthesized by treating resorcinol with ethyl-2-ethylacetoacetate and ethyl acetoacetate
respectively. Compounds 20 and 23 are the alkylation product of 19 and 22 respectively while
compound 21 and 24 are the click were synthesized by performing click reactions between
compound 2 and compound 20 and 23 respectively (see Schemes 24-29). Moreover, compound
25 and 26 (see Schemes 30 and 31) were synthesized by decapitating compounds 11 and 14
respectively using CsOH/KOH as a strong base and 95% ethanol/THF as solvent to make them
water soluble for their biological distribution studies. This work is currently underway as well.
Click reaction is a simple, wide in scope and high yielding reaction between azide and
alkyne which was performed using Cu(I)I as catalyst, and 50:50 mixture of CH3CN and THF as
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solvent whereas N,N-Diisopropylethylamine (DIPEA) was used as a proton scavenger helping
to avoid unwanted side-reactions. Most of the synthesized compounds were purified and isolated
in good yields, and characterized by NMR spectra (1H, 13C, and 11B), FTIR spectra, high
resolution mass spectral analysis and elemental analysis where possible. The FTIR spectra of
compounds containing carborane cage showed strong bonds between 2580 and 2586 cm-1
corresponding to υ (B-H). The presence of carborane cage was also evident from 1H, 13C, and
11

B NMR spectra. Mass spectral data of compounds 11, 12, 13 and 14 confirmed their

identifications. High resolution mass spectral data for the carborane-appended compounds 11,
12, 13, 14 showed prominent peaks at m/z 407.3199 (M+H), 407.200 (M+H), 494.3407 (M+3H)
and 738.5232 (M+H) respectively (see appendix). The elemental analysis was performed with
compounds 11, 12, 13, 14, 15, 16, 17 and 18 which are discussed in experimental section.
The click reaction (Cu(I) I-catalyzed azide-alkyne cycloaddition reaction) has been found
to be a facile approach for the synthesis of carborane-appended biocompatible compounds
potentially suitable for BNCT applications. Carborane-appended derivatives of various organic
compounds (4-nitroimidazole, 2-nitroimidazole, phenothiazine, 1, 3,4-thiadiazole-2, 5-dithiol,
adenine, 6-chloropurine, 3’,5’-dihydroxyacetophenone and coumarin compounds) were
synthesized in very good yields. A multi-step organic synthetic methodology was established to
attach a polyhedral carborane cage to these compounds. This methodology includes the
alkylation reaction of the selected organic compounds followed by their conjugation with
carboranyl azide compound via click reaction. Compounds 11 and 14 were made water soluble
by the decapitation of their carborane cage. Cytotoxicity study of the compounds 21 and 24 were
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performed and found to be non-toxic. Bio-distribution studies of these compounds will provide
the idea about their potential applicability in cancer therapeutics.
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CHAPTER 13
FUTURE DIRECTIONS
In the future, more similar studies will be performed by selecting various other organic
compounds as a starting material. All of the synthesized compounds could be made water soluble
in order for their biological distribution studies. The cytotoxicity of the remaining compounds
will also be tested in order to determine their biological activity. It is also possible to encapsulate
the products with liposomes for their effective delivery into the body. Moreover, since all the
products synthesized contain natural boron (20% 10B and 80% 11B), this work will be repeated
using 10B enriched carborane before BNCT.
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APPENDIX A

LIST OF NMR, FTIR, AND MS SPECTRUMS OF
ALL SYNTHESIZED COMPOUNDS

80
Compounds 1 & 2: 13C, 1H and 11B NMR Spectrum
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82
Compound 3: 13C and 1H Spectrum
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Compound 4: 13C and 1H Spectrum

84
Compound 5: 13C and 1H Spectrum
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Compound 6: 13C and 1H Spectrum

86
Compound 7: 13C and 1H Spectrum

87
Compound 8: 13C and 1H Spectrum
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Compound 9: 13C and 1H Spectrum

89
Compound 10: 13C and 1H Spectrum

90
Compound 11: NMR (13C, 1H, 11B), FTIR and MS Spectrum
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Compound 12: NMR (13C, 1H, 11B), FTIR and MS Spectrum
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Compound 13: NMR (13C, 1H, 11B), FTIR and MS Spectrum
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Compound 14: NMR (13C, 1H, 11B), FTIR and MS Spectrum
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Compound 15: 13C, 1H, and 11B NMR Spectrum
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Compound 17: 13C, 1H, and 11B NMR Spectrum
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Compound 18: 13C, 1H, and 11B NMR Spectrum
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Compound 19: 13C and 1H NMR Spectrum
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Compound 20: 13C and 1H NMR Spectrum
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Compound 21: 13C, 1H, and 11B NMR Spectrum
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Compound 22: 13C and 1H NMR Spectrum

113
Compound 23: 13C and 1H NMR Spectrum
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Compound 24: 13C, 1H, and 11B NMR Spectrum
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116
Compound 25: 13C, 1H, and 11B NMR Spectrum
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118
Compound 26: 13C, 1H, and 11B NMR Spectrum
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